Drug Trial Radar · NCT07933224
A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The high-fat meal food effect part adopts a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. Based on the results of the high-fat meal food effect trial, the sponsor and the principal investigator will comprehensively analyze and determine whether a low-fat meal food effect trial needs to be conducted.
Conditions
- Healthy Volunteers
Interventions
HS-10382Drug
Drug: HS-10382 Comes in 40 mg tablets and taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of PK parameters of HS-10382: CmaxTime frame: 96 hours after administration of HS-10382
- Evaluation of PK parameters of HS-10382: AUC0-tTime frame: 96 hours after administration of HS-10382
- Evaluation of PK parameters of HS-10382: AUC0-∞Time frame: 96 hours after administration of HS-10382
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.